Tag: obligation

Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed

DUBLIN, July 25, 2025 (GLOBE NEWSWIRE) -- Fusion Fuel Green PLC (NASDAQ: HTOO) (“Fusion Fuel” or the “Company”), a provider of integrated energy solutions, today announced that, in July 2025, its majority-owned operating subsidiary, Al Shola Al Modea Gas Distribution LLC (“Al Shola Gas”), confirmed a number of new projects for the installation and maintenance of liquefied petroleum gas (“LPG”) systems and the supply of bulk LPG across multiple large-scale residential and commercial developments in Dubai, United Arab Emirates.

ZEELAND, Mich., July 25, 2025 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today reported financial results for the three and six months ended June 30, 2025.

With a production budget that surpasses Squid Game Season 1, Trigger emerges as Netflix’s next high-stakes Korean mega-production

Major Offshore Acreage Expansion Creates New Growth Platform in the Gulf of Thailand

Orrön Energy AB (“Orrön Energy”) will publish its financial report for the second quarter 2025 on Wednesday, 6 August 2025 at 07:30 CEST, followed by a webcast at 14:00 CEST.

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)